Novel Drug Delivery Systems (NDDS) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Novel Drug Delivery Systems (NDDS) Market Trends and Insights

Rising Prevalence of Chronic Diseases

Cardiovascular and diabetic conditions affected more than 1.23 billion people globally in 2024 and continue to swell clinical demand for sustained-release therapies that reduce dosing frequency^{[1]Source: World Health Organization, “Cardiovascular diseases (CVDs),” who.int} . Long-acting platforms such as the intravesical TAR-200 device illustrate this shift, delivering gemcitabine continuously over multiple months and achieving median response duration of 25.8 months, markedly higher than intermittent regimens. Regulators respond with guidance that favors integrated drug–device products able to improve adherence, reinforcing investment in implantable and transdermal formats.

Growing Adoption of Biologics & Large-Molecule Drugs

Escalation in monoclonal antibodies and RNA-based therapeutics elevates formulation complexity and stimulates nanoparticle innovation. Pfizer’s ponsegromab trial underscores the benefit—optimized delivery improved performance in cancer cachexia patients. Vendors consequently expand lipid nanoparticle capacity; Lonza added multiple dedicated suites in 2025 to ease supply shortages. Cold-chain logistics and patient ease-of-use remain critical, widening prospects for temperature-controlled packaging and self-injecting wearables.

Digital-Therapeutic Integration Enabling Smart Delivery

Connected devices advance from passive dispensing toward continuous data capture. Global revenue for smart delivery systems approached USD 12 billion in 2024. FDA cybersecurity guidelines released in 2024 impose secure-by-design requirements, prompting early-stage redesigns but ensuring long-term patient safety^{[2]Source: U.S. Food and Drug Administration, “Cybersecurity in Medical Devices: Refuse to Accept policy,” fda.gov} . Artificial intelligence embedded in injectors and inhalers now supports algorithm-directed dose titration.

Expansion of mRNA / Gene-Therapy Pipelines

More than 200 gene-therapy trials launched in 2024, accentuating the bottleneck in vector and LNP capacity. Cytiva, Lonza and other suppliers committed multi-million-unit plants to satisfy projected demand to 2030. Tissue-targeting challenges and immunogenicity concerns sustain R&D in novel capsids and biodegradable carriers, while regulatory agencies maintain rigorous safety thresholds for viral or non-viral vectors.

Stringent Combination-Product Regulations

Revised FDA and EMA guidelines require exhaustive drug–device interaction studies, inflating budgets by as much as USD 100 million and extending timelines up to two years. J&J secured Breakthrough Therapy Designation for TAR-200 yet still navigated extensive post-market commitments, highlighting the difficulty for smaller innovators. Divergent regional rules further complicate global launches.

High Device Cost in LMICs

Connected auto-injectors and implantables cost 10-20 times more than oral generics, limiting access in resource-constrained regions. Procurement agencies in Latin America and Africa require localized manufacturing or tiered pricing; however, limited regulatory capacity delays approvals for sophisticated devices. Companies are piloting simpler, single-function variants to lower cost while preserving core therapeutic benefit.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Route of Administration: Oral Dominance Faces Digital Disruption

Oral therapies commanded 48.70% of New Drug Delivery Systems market share in 2025, yet growth moderates as digital implants and long-acting injectables demonstrate superior adherence. Implantable formats are projected to deliver a 8.72% CAGR to 2031, supported by breakthroughs such as Vivani Medical’s GLP-1 implant that filled its first human study in four weeks. Injectable routes benefit from the biologics wave, while inhaled delivery attracts neurological and respiratory pipeline investments.

Patient preference, manufacturing scalability and reimbursement convenience underpin oral system resilience through 2030. However, smart pill sensors and micro-fluidic implants that log dosing create fresh value propositions for chronic disease management. Nasal and ocular options prosper in niche neurological and ophthalmic settings. Ultimately, route selection is increasingly dictated by molecular characteristics and personalized care models rather than historical convenience.

By Technology/System Type: Smart Connectivity Reshapes Traditional Platforms

Auto-injectors retained 22.05% share of the New Drug Delivery Systems market size in 2025 on entrenched supply chains and clinician familiarity. Smart and connected devices, however, are advancing at a 9.18% CAGR as cloud-linked patches and app-integrated pens transform medication into data streams. Nanoparticle carriers, essential for mRNA therapeutics, underpin capacity expansions at Lonza and similar CDMOs.

Needle-free jet injectors reduce vaccination anxiety and speed mass-immunization programs, while microneedle patches gain traction in dermatology and vaccine delivery. Wearable infusers capable of delivering 5-50 mL biologics at home remove infusion-center bottlenecks. The technology race increasingly favors modular platforms adaptable across molecules, thereby compressing development cycles and enhancing portfolio ROI.

By Therapeutic Application: Oncology Leadership Challenged by Neurological Innovation

Oncology contributed 33.05% of New Drug Delivery Systems market revenue in 2025, supported by antibody–drug conjugates, radiopharmaceuticals and device-enabled intratumoral therapies. J&J’s pasritamig showcased early anti-tumor activity with outpatient dosing every six weeks. Neurological disorders, including Parkinson’s and Alzheimer’s, are forecast to record a 9.36% CAGR, as BBB-penetrating nanoparticles and continuous infusion pumps address unmet needs.

Diabetes maintains momentum through closed-loop insulin systems integrating real-time glucose data, while cardiovascular therapies shift toward once-quarterly depot injections. Infectious disease platforms leverage rapid-fill needle-free injectors for pandemic preparedness. Cross-application platforms permit scale economies, aligning R&D cost with expanded indication breadth.

By End User: Hospital Infrastructure Supports Home-Care Transition

Hospitals held 53.10% share of New Drug Delivery Systems market in 2025, reflecting embedded infusion suites and surgical implant capabilities. Home-care settings, anticipated to post a 10.12% CAGR, capitalize on reimbursement reforms that finance at-home biologic administration. Ambulatory centers exploit minimally invasive implants, enabling same-day discharge.

Specialty clinics partner with device makers for disease-focused programs. Remote monitoring dashboards linked to connected injectors reduce unscheduled hospital visits, further reinforcing the migration to decentralized care. Successful systems therefore must balance clinical precision with ease of patient self-use.

Geography Analysis

North America retained 41.90% of New Drug Delivery Systems market revenue in 2025, supported by fast regulatory pathways and payer acceptance of high-value devices. Breakthrough Therapy designations accelerate adoption, yet rising scrutiny of cybersecurity prolongs time-to-market for connected delivery tools. Capacity shortfalls for lipid nanoparticles prompt partnerships with Asian CDMOs.

Asia-Pacific is projected to log a 10.66% CAGR through 2031. Regional governments expand universal health coverage and incentivize domestic manufacturing. China’s policy to localize high-end medical technology has spurred joint ventures for smart auto-injectors, while India’s generics producers eye value capture in cost-effective microneedle patches.

Europe remains mature but regulation-intense. The Medical Device Regulation introduces dual compliance needs that delay launches but elevate safety standards. Sustainability imperatives accelerate interest in recyclable packaging and long-acting formulations. Brexit’s separate U.K. pathway demands parallel submissions, adding complexity but not materially eroding demand.

Regulatory Landscape

Regulation for novel drug delivery systems continues to focus on combination-product controls and harmonized quality systems across key markets. In the United States, the FDA Quality Management System Regulation (QMSR) became effective on February 2, 2026, incorporating ISO 13485:2016 by reference and setting new quality-system expectations for manufacturers of drug delivery devices and drug-device combination products.

For integral drug-device combinations in Europe, EU MDR Article 117 requires a Notified Body Opinion (NBOp) to confirm conformity with Annex I General Safety and Performance Requirements (GSPRs) when the device constituent does not hold a CE mark. That increases the importance of early Notified Body engagement for marketing authorization dossiers. Regulators also continue to emphasize performance and safety evidence, including FDA work around Essential Drug Delivery Outputs (EDDO) and guidance affecting transdermal systems, which raises documentation and verification requirements for delivery performance, human factors, and lifecycle risk management.

Value Chain Analysis

The NDDS value chain covers API and excipient suppliers (including specialized polymers, adhesives, and nanoparticle inputs), device component manufacturers (primary containers, needles, on-body mechanisms, sensors), platform developers, and integrated CDMOs that increasingly provide end-to-end services across formulation, device integration, and fill-finish. CROs and specialist test labs support clinical development through device performance, biocompatibility, and delivery verification work, while cold-chain and specialized logistics providers help distribute temperature-sensitive biologics, mRNA, and gene-therapy related products.

Bottlenecks cluster in scale-up and quality control for complex products, notably lipid nanoparticle manufacturing capacity and the characterization and batch-to-batch consistency testing needed for nanotechnology-enabled delivery systems. As portfolios shift toward self-administration and large-volume subcutaneous formats, platform standardization and supplier qualification become more important across the chain, from component traceability through post-market surveillance, particularly for connected devices that require secure digital tracking and lifecycle software controls.

Market Opportunities and Future Outlook

Opportunity is increasing around high-volume subcutaneous administration and at-home delivery formats that shift complex biologics from infusion settings to self-administration. Recent company activity provides specific evidence of this direction, including Halozyme entering 2026 collaborations to apply ENHANZE for subcutaneous oncology targets with GSK (including antibody-drug conjugates) and to apply Hypercon technology with Vertex and Oruka to reduce injection volume.

Oral delivery of biologics is also showing near-term commercialization momentum through visible licensing activity. Novo Nordisk partnered with Vivtex (February 2026) to license oral drug-delivery technologies for oral biologic medicines in obesity and diabetes, reflecting demand for patient-centric, needle-sparing administration in chronic metabolic disease. In parallel, the FDA Office of Combination Products maintaining Essential Drug Delivery Outputs (EDDO) as a 2026 priority is increasing incentives for standardized verification and control of delivery performance, creating a clear need for platform device makers and CDMOs that can industrialize repeatable test methods, design controls, and compliant manufacturing for drug-device combinations and smart delivery systems.